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Abstract
Besides their role in the formation of thrombus during haemostasis, it is becoming clear that
platelets contribute to a number of other processes within the vasculature. Indeed, the
integrated function of the thrombotic and inflammatory systems, which results in platelet-
mediated recruitment of leukocytes, is now considered to be of great importance in the
propagation, progression and pathogenesis of atherosclerotic disease of the arteries. There are
three scenarios by which platelets can interact with leukocytes: (1) during haemostasis, when
platelets adhere to and are activated on sub-endothelial matrix proteins exposed by vascular
damage and then recruit leukocytes to a growing thrombus. (2) Platelets adhere to and are
activated on stimulated endothelial cells and then bridge blood borne leukocytes to the vessel
wall and. (3) Adhesion between platelets and leukocytes occurs in the blood leading to
formation of heterotypic aggregates prior to contact with endothelial cells. In the following
review we will not discuss leukocyte recruitment during haemostasis, as this represents a
physiological response to tissue trauma that can progress, at least in its early stages, in the
absence of inflammation. Rather we will deal with scenarios 2 and 3, as these pathways of
platelet–leukocyte interactions are important during inflammation and in chronic inflammatory
diseases such as atherosclerosis. Indeed, these interactions mean that leukocytes possess
means of adhesion to the vessel wall under conditions that may not normally be permissive of
leukocyte–endothelial cell adhesion, meaning that the disease process may be able to bypass
the regulatory pathways which would ordinarily moderate the inflammatory response.
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Introduction
It is now widely recognised that platelets play an import role in
the pathology associated with cardiovascular diseases. The
literature on the contribution of platelets to symptomatic
atherothrombotic disease, which is predicated on the formation
of a mural thrombus in diseased arteries, is extensive. As this
aspect of platelet biology is well developed and is already the
target of a number of successful and well validated therapeutic
pathways, we do not propose to address it in the current
discussion. The reader is directed to a recent review of this area
for additional information [1].
Here, having briefly revisited endothelial cell (EC) mediated
pathways of leukocyte recruitment during inflammation, the roles
of platelets in the recruitment and function of leukocytes in
cardiovascular diseases will be discussed. In particular, the
molecular basis of the interactions between platelets, leukocytes
and the vessel wall are reviewed. The ability of immobilised
platelets to recruit leukocytes is well established and discussed in
detail. However, the developing field of leukocyte–platelet
aggregation in circulating blood is also addressed, including
emerging paradigms on the importance of platelet microvesicles
(PMV) in the regulation of leukocyte recruitment in cardiovas-
cular diseases. Finally, the current therapeutic options for
intervening in the platelet-mediated recruitment of leukocytes in
cardiovascular diseases will be discussed.
Leukocyte adhesion during resolving inflammation
In vertebrates, infection or tissue trauma cause the rapid initiation
of an acute and resolving inflammatory response. The identity of
the leukocytes within the tissue infiltrate vary with time and
throughout the evolution of the inflammatory response in order
that the requirements for repair of the affected tissues and the
development of an adaptive immune response are matched to the
specialised functions of the different leukocyte subsets [2].
The molecular processes that support leukocyte recruitment in
post-capillary venules (the site where leukocytes are recruited
during acute inflammation) are well described (Figure 1). Thus,
local inflammatory mediators, such as histamine or cytokines
(e.g. tumour necrosis factor-a – TNF), activate ECs resulting in
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the expression of specialised adhesion receptors that form short
lived bonds with counter ligands on the leukocyte surface [3–5].
Thus, E- and P-selectin and the immunoglobulin super-family
(IgSF) member, vascular adhesion molecule-1 (VCAM-1), are the
major receptors that tether leukocytes from rapidly flowing blood
[6]. The sequential formation and dissolution of these bonds
supports a characteristic and dynamic form of adhesion, referred
to as rolling [7] which does not require leukocyte activation.
However, leukocyte migration through the vessel wall and into the
inflamed tissue is dependent upon the receipt of an activating
stimulus [7, 8]. Peptide agonists of the chemokine family are the
major activating stimuli presented to rolling leukocytes in order to
stabilise adhesion [9, 10], although numerous other mediators
have been reported to play a role in leukocyte recruitment under
some inflammatory conditions (e.g. platelet activating factor
[PAF] and leukotriene-B4 [LTB4]) [11–14]. These signals result
in remodelling of the cytoskeleton and activation of the b1 and
b2-integrin adhesion molecules that provide firm adhesion. The
integrins also support apical and trans-EC migration of adherent
leukocytes using intercellular adhesion molecule-1 (ICAM-1) and
VCAM-1 as counter ligands [9]. Efficient onward migration after
chemokine activation also requires additional downstream signals.
Thus, neutrophils and T-lymphocytes require a prostaglandin-D2
(PGD2) signal to undertake diapedesis in vitro [15]. In addition,
molecules at the EC junction have been implicated in the
regulated trafficking of leukocytes, including CD31 (platelet-
endothelial cell adhesion molecule-1 – PECAM-1), CD99 and
family members of the junctional adhesion molecules (JAM)
family, e.g. JAM-C [16, 17].
Platelets are a sufficient substrate to support the
recruitment, activation and migration of blood borne
leukocytes
There is now an increasing awareness that aberrant pathways of
leukocyte recruitment might be established in disease states [18].
Of relevance here was the increasing realisation that platelets might
promote leukocyte adhesion during inflammation, in particular the
concept that platelet interactions with the vessel wall might lead to
inappropriate leukocyte recruitment in atherosclerosis. Such
hypotheses were predicated on the assumption that activated
platelets were capable of recruiting leukocytes from the blood. This
was a reasonable expectation, as platelet a-granules contain P-
selectin which is expressed upon activation [19, 20]. In addition,
they release leukocyte activating agents (see below for details).
Early studies showed conclusively that monolayers of
immobilised, spontaneously activated platelets were able to
recruit flowing leukocytes using P-selectin [21, 22]. Both
granulocytic and mononuclear leukocytes were captured effi-
ciently from flow and could roll continuously across the
monolayer without apparent signs of activation. Importantly, if
the platelets were activated by thrombin (i.e. through protease-
activated receptors [PAR] – PAR1 and PAR4), neutrophils were
rapidly activated through the CXCR2 receptor, putatively by
platelet-derived CXCL7 (NAP-2) [23]. Other studies using
activated platelets have identified alternative pathways of neutro-
phil activation. Thus, thrombin stimulated platelets activate
neutrophils through PAF and LTB4 [24], while platelets bound
to and activated by collagen type 1, activated neutrophils through
PAF [25]. Interestingly, LTB4 is not a platelet-derived eicosanoid,
but can be synthesised by neutrophils from platelet-derived
arachidonic acid [26], making it an exemplar of transmetabolic
activity requiring the integrated activity of the haemostatic and
immune systems. Other CXC chemokines have been reported in
platelets, although their function in leukocyte recruitment remains
undetermined. Thus, a full-length cDNA for CXCL5 (ENA 78)
was cloned from human platelets [27], although transcribed
protein was not measured. In addition, rabbit platelets contain
preformed and stored CXCL8 (IL-8), which was secreted upon
platelet activation [28].
Using activated neutrophils, the b2-integrin, CD11b/CD18
(aMb2; Mac-1) supported immobilisation on the platelet mono-
layer using platelet fibrinogen as a counter ligand [29, 30].
Interestingly, immobilised platelets could also provide signals
through specific receptors (e.g. P-selectin and CD31) that
regulated the velocity and direction of neutrophil migration [31,
32]. Moreover, neutrophils migrating on a platelet monolayer
formed large embolising aggregates when they came into contact
with each other [33]. Diacovo et al. showed that platelets
immobilised on fibronectin-coated polycarbonate filters, sup-
ported neutrophil migration towards an exogenous chemotactic
agent added below the filter [29].
Figure 1. The multi-step leukocyte adhesion cascade: (1) Endothelial cells at a site of inflammation are activated by stromal derived inflammatory
cytokines such as TNF-a, IL-1b and IFN-g. Induction of transcriptional activity results in the expression of adhesion molecules and chemokines which
coordinate leukocyte recruitment. (2) Leukocytes are recruited from flowing blood by specialised receptors of the selectin family and VCAM-1, which
also support rolling adhesion. (3) Chemokine signals activate the b1 and b2 integrins on rolling leukocytes. (4) Adhesion is stabilised and the
leukocytes become firmly adherent to the endothelial cell. (5) In response to additional signals, e.g. from PgD2, the leukocyte cytoskeleton undergoes
remodelling driving shape change (spreading) and dynamic integrin-mediated migration. (6) Leukocytes migrate across and through the endothelial cell
monolayer and onwards into tissue.
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Platelets can bind to appropriately stimulated
endothelial cell monolayers
The concept that platelets may interact directly with ECs
conditioned by an inflammatory environment has received
increasing attention. Ordinarily, ECs present an anti-thrombotic
surface to flowing blood by releasing nitric oxide (NO) and
prostacyclin (PGI2) and through expression of CD39 [34].
Signalling into the platelet by PGI2 and NO maintains high
levels of cyclic nucleotides within the platelet cytoplasm,
thereby antagonising all the known pathways of platelet activation
[35–37], while the ectonucleotidase activity of CD39 enzymati-
cally degrades ADP, one of the two major feedback agonists
involved in platelet activation. Early work thus assumed that EC
‘damage’ was required to expose matrix to which platelets could
bind [38, 39]. This paradigm has been modelled in vitro using
sub-confluent ECs, where matrix proteins readily recruit platelets
from perfused blood [40]. However, more recent in vitro studies
show that platelets can adhere directly to endothelium when either
the ECs and/or platelets are activated by agents such as thrombin
or ADP (platelets) or the cytokines IL-1b, TNF-a or TGFb1 (EC)
[39, 41–54]. Figure 2 shows the routes by which platelets may
facilitate the recruitment of leukocytes to the vessel wall that are
discussed in this review.
Intravital experiments in mice showed platelet adhesion to
mesenteric venules following treatment with calcium ionophore
and to arteries at sites of atheroma formation [55–57]. In addition,
stimulation of the murine cremaster muscle for 4 hours by topical
application of TGF-b1 results in platelet deposition in post-
capillary venules [45]. Platelet adhesion in these models was
supported by bridging of platelet aIIb/b3 integrin to EC avb3
integrin by von Willebrand factor (VWF) [41, 42, 44, 49, 52, 55]
with a possible contribution from P-selectin [58]. An interesting
mechanism for delivering platelets to EC was reported by Van
Gils et al. [59] who showed that platelets in aggregates with
monocytes (a phenomenon discussed in detail below) relocated to
the rear of the leukocyte before detaching and adhering to an EC
upon monocyte diapedesis. One can speculate that this process
might be relevant to the secondary recruitment of blood borne
leukocytes to the vessel wall during inflammation.
Platelets adherent to the vessel wall can recruit blood
borne leukocytes
The concept that platelet deposition to the vessel wall can
promote the recruitment of leukocytes now has substantial
experimental support. In vitro, numerous studies demonstrate
platelet-mediated leukocyte recruitment to adhesive substrates of
matrix proteins or ECs. Thus, when whole blood was perfused
across sub-confluent cultures of ECs, platelets bound to exposed
matrix and subsequently supported the recruitment and activation
of perfused neutrophils [60]. In flow based models of vascular
Figure 2. Mechanisms of platelet-mediated leukocyte recruitment: (1) appropriately activated endothelial cells express a matrix of VWF on their
surface to which platelets are recruited and activated. Platelet presented P-selectin then forms an adhesive bridge between the endothelial surface and
blood borne leukocytes. (2) Platelets form heterotypic aggregates with leukocytes in the circulation in a P-selectin dependent manner. Aggregates are
then recruited to the VWF on the surface of appropriately activated endothelial cells. (3) Inflammatory cytokines induce transcriptional programmes in
endothelial cells which result in the expression of adhesion molecules and chemokines that support leukocyte adhesion. Leukocytes in heterotypic
aggregates which are recruited to the endothelial cell surface posses additional platelet borne receptors. These can in turn support the secondary
adhesion of un-aggregated leukocytes. (4) Upon activation platelets shed microvesicles which bind directly to endothelial cells. Microvesicle borne
inflammatory cytokines induce transcriptional programmes in endothelial cells which result in the expression of adhesion molecules and chemokines
that support leukocyte adhesion. (5) P-selectin bearing PMV bind to appropriately activated endothelial cells. Platelet presented P-selectin then forms
an adhesive bridge between the endothelial surface and blood borne leukocytes. (6) P-selectin bearing PMV form heterotypic aggregates with
leukocytes in the circulation. Aggregates are then recruited to VWF on appropriately stimulated endothelial cells utilising microvesicle borne adhesion
receptors.
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damage, platelets deposited from whole blood onto collagen could
recruit leukocytes [61, 62], and this was most efficient under
conditions of disturbed flow in a model recapitulating the
environment found downstream of atherosclerotic plaque. In this
model, platelets and leukocytes were delivered to the substrate in
a continuously rotating vortex which developed downstream of a
step in the flow chamber [63]. Using whole blood under flow
conditions, even platelets that were sparsely adherent to ECs
could efficiently recruit neutrophils and monocytes [45, 61].
Interestingly, secondary recruitment of monocytes to ECs was
supported by platelet-monocyte aggregates that were adherent to
the endothelium, with platelet P-selectin acting as a bridge to
deliver flowing monocytes to the EC [64]. Where it was
characterised in these studies, authors showed that leukocyte
capture was mediated by platelet P-selectin and stable adhesion
was supported by leukocyte b2-integrins.
An important aspect of these studies is the diversity of
leukocytes recruited by vessel wall adherent platelets. Thus, these
as well as other reports [65, 66] detailed the platelet-mediated
recruitment of neutrophils, monocytes, dendritic cells, T-lympho-
cytes, B-lymphocytes and NK-cells to endothelium. This lack of
specificity is not surprising, as the counter ligand for P-selectin, P-
selectin glycoprotein ligand-1 (PSGL-1), is present on many
leukocyte subsets. However, a number of observations describing
specificity in the platelet-mediated recruitment of leukocytes are
of particular interest. Kuckleberg et al. [45] demonstrated that
monocytes were preferentially recruited by EC adherent platelets
in an EC-smooth muscle cell co-culture model of the athero-
sclerotic artery wall. The ECs were activated by TGF-b1
generated in co-culture, and could recruit flowing platelets to
surface VWF, a model that could be recapitulated by activating
ECs with recombinant TGF-b1. Specificity for monocytes arose
through EC production of CCL2 (MCP-1), which preferentially
stabilised the adhesion of monocytes captured from flowing
whole blood by platelet P-selectin. Two other groups using intra-
vital observations in atherosclerotic mice (ApoE/) also
observed chemokine dependent specificity of monocyte adhesion
to the carotid artery [56, 67]. In these studies, adhesion of
platelets which presented P-selectin, and deposition of platelet-
derived CCL5 (Regulated on Activation, Normal T cell Expressed
and Secreted – RANTES) and CXCL4 (platelet factor-4 – PF-4)
onto the endothelium, was responsible for increased monocyte
adhesion. Schulz et al. demonstrated a similar paradigm on
cytokine stimulated human ECs [68]. Here, platelets binding from
whole blood captured leukocytes through P-selectin and mono-
cytes were subsequently activated by EC derived CX3CL-1
(fractalkine). In addition, blockade of CX3CR1 by injection of a
function neutralising antibody into the ApoE/ mouse, inhibited
the adhesion of WEHI-274.1 cells (a monocytic cell line) to the
carotid artery. Thus, although the initial tethering of leukocytes by
platelet P-selectin may not be selective, specificity for recruitment
of leukocyte subsets, in particular monocytes can be achieved by
the presentation of chemokines, the receptors for which are
restricted to a limited repertoire of leukocytes.
The formation of heterotypic leukocyte–platelet
aggregates in the blood
The formation of platelet–leukocyte aggregates in the blood, and
the subsequent presentation of platelet adhesion receptors on the
leukocyte, would mean that circulating leukocytes would possess
a means of adhesion to the vessel wall that is not normally present
during inflammation. The formation of heterotypic platelet–
leukocyte aggregates in blood is dependent upon platelet activa-
tion [69]. This leads to platelet P-selectin binding to leukocyte
PSGL-1 to establish heterotypic adhesion [70]. Indeed, blocking
the function of P-selectin or PSGL-1 with neutralising antibodies
is an effective means of ablating aggregate formation [70–72].
Importantly, intercellular adhesion is further stabilised directly or
indirectly (via fibrinogen bridging) by other receptors, e.g. GPIb
and aIIbb3 integrin on platelets and the b2 integrins (in particular,
CD11b/CD18) on leukocytes [73, 74].
The formation of platelet–leukocyte aggregates occurs with a
low incidence even in healthy individuals. Indeed, platelet–
monocyte aggregates appear to be more common in healthy
children than in healthy adults [75], indicating that their occurrence
might change with age. Interestingly, there is a positive correlation
between the number of circulating leukocyte–platelet aggregates
and the severity of inflammatory and infectious diseases. Thus, an
increase in aggregates is reported in diabetes and rheumatoid
arthritis, diseases associated with accelerated formation of ather-
oma and increased risk of athero-thrombotic disease [76–78]. An
increase in aggregates has also been observed in inflammatory
bowel disease [79] and ischaemic heart failure [80]. Interestingly,
their incidence is also increased in bacterial infections [81]. Indeed,
monocytes with adherent platelets are recruited to sites of
Leishmania major infection [81], while Staphylococcus aureus
promotes the formation of neutrophil–platelet aggregates in the
circulation [82].
The formation of platelet–leukocyte aggregates (in particular
platelet-monocyte aggregates) occurs in atherosclerosis and
athero-thrombotic disease. Thus, in both stable coronary artery
disease or during coronary or cerebral infarction, the number of
circulating aggregates increases significantly [83–89]. Moreover,
the incidence of aggregates increases with independent risk
factors for cardiovascular and cerebrovascular disease, such as
hypertension [90, 91]. Importantly, increases in circulating
platelet–monocyte aggregates may themselves be an independent
risk factor for cardiovascular and cerebrovascular disease, or at
least, their abundance can be used to stratify patients on the basis
of predicted outcome after acute myocardial infarction [92].
Interestingly, experiments tracking autologous infused biotiny-
lated platelets (activated ex vivo) in animal models demonstrate
that the number of circulating monocyte–platelet aggregates may
be a more sensitive indicator for in vivo platelet activation than
circulating neutrophil-platelet aggregates or P-Selectin-positive
non-aggregated platelets. Indeed, it has been demonstrated that
after percutaneous coronary intervention (PCI), there is an
increased number of circulating monocyte–platelet aggregates
(and, to a lesser extent, neutrophil-platelet aggregates), but not
P-selectin-positive platelets in peripheral blood. These data imply
a rapid and efficient association between circulating leukocytes
and activated platelets, making the later difficult to observe.
Thus, these studies indicate that heterotypic platelet–monocyte
aggregates are associated with the progression of atherosclerotic
disease and may contribute to the severity of symptomatic athero-
thrombotic disease. However, it is notable that a direct role of
heterotypic aggregate formation in the recruitment of monocytes
(or other leukocytes) to ECs overlying atherosclerotic plaque has
yet to be described.
The role of PMV in promoting leukocyte recruitment
Microvesicles are heterogeneous plasma membrane derived
particles, 100–1000 nm in diameter, which can be detected in
blood, urine and other bodily fluids [93]. They are released from
cells of the vasculature, including platelets, ECs and leukocytes,
and specific populations can be identified using appropriate
methodology (e.g. flow cytometry), as they express surface
markers derived from their cell of origin. There is mounting
evidence that microvesicles play a physiological role in inflam-
mation [94].
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Microvesicles are released from activated cells and inflamma-
tory diseases are associated with increased numbers of circulating
microvesicles [95]. Microvesicles may be incorporated directly
into the plasma membrane [96] or internalised by a recipient cell
[97], thereby delivering vesicle contents. As microvesicles
transport a wide range of molecular cargo, including DNA [98],
mRNA [99], micro-RNA [100], membrane and signalling lipids
[101] and proteins [102], there is the potential for important
modification of recipient cell function. Importantly, this can
include alterations in their adhesion to other cell types.
Microvesicles derived from activated platelets (PMV) are
considered to be the most abundant population in human blood
[103]. In vitro, PMV have been generated in response to shear
stress, thrombin, calcium ionophore, ADP, collagen and collagen
related peptide [104–107]. Interestingly, proteomic studies on
populations of microvesicles derived using different platelet
agonists demonstrate the formation of heterogeneous populations.
Thus, using thrombin or shear stress as distinct routes to platelet
activation, resulted in microvesicles that differed in abundance, as
well as the identity of their protein cargos [107]. Importantly,
megakaryocytes, which are the bone marrow progenitor cells
from which platelets mature, also release microvesicles into the
blood. This population of microvesicles shares surface markers
such as CD41 (aIIb-integrin subunit) and CD42b (GPIb) with
PMV [103]. Thus, studies that use these molecules to discriminate
a platelet-derived population of microvesicles should be inter-
preted with caution, as it is possible that the predominant
population of microvesicles expressing CD41 and CD42b are
derived from megakaryocytes. Only upon activation do platelets
release microvesicles bearing CD62P (P-selectin) which may
discriminate the origin of these populations.
An increased incidence of circulating PMV is associated with
a number of diseases. In diabetic retinopathy, the number of PMV
was associated with the severity of disease [108], while the levels
of PMV circulating in type-1 diabetics correlated with the degree
of pro-atherogenic dyslipidaemia [109]. There was a correlation
with vascular dysfunction (assessed by measuring arterial elas-
ticity and flow-dependent vasodilatation of the brachial artery)
[110] in patients with Type-2 diabetes. Interestingly, the number
of PMV was higher in patients with acute coronary syndromes
than those with stable angina [111], implying an association with
the onset of athero-thrombotic disease.
The roles of PMV in inflammation and pathogenesis of
inflammatory disease is not well understood. However, they
possess adhesion receptors such as GPIb, aIIbb3-integrin and
P-selectin, meaning that they could interact with the vessel wall
and circulating leukocytes to promote recruitment of the later.
Surprisingly, their role in leukocyte adhesion is sparsely reported.
Tersteeg et al. [112] showed that platelets adherent to physio-
logical substrates in vitro and in vivo elaborated extensive (100’s
mm) flow-induced membrane protrusions (FLIPRs) which deliv-
ered microvesicles to neutrophils and monocytes rolling in a P-
selectin dependent manner. These interactions lead to leukocyte
activation using increased CD11b expression and the shedding of
CD62L (L-selectin) as markers. The interaction of PMV with ECs
has also been studied. Mause et al. [113] demonstrated that PMV
rolled on IL-1b stimulated human microvascular ECs using P-
selectin and GP1b. This was sufficient for the deposition of
microvesicle derived CCL5 onto the ECs, leading to increased
arrest of perfused monocytes [113]. Barry et al. [114, 115]
observed that the adhesion of monocytes and the monocytic
leukaemia cell line, THP-1, to ECs treated with PMV was
increased, an outcome that was attributed to the activation of both
ECs and leukocytes by the delivery of arachidonic acid (AA) from
the microvesicles. Lindemann et al. showed that activated
platelets could synthesise IL-1b which was incorporated into
PMV [116]. Importantly, IL-1b-mediated activation of ECs by
these microvesicles resulted in neutrophil adhesion, although the
molecular basis of recruitment was undescribed. PMV also up-
regulated adhesion receptors (including E-selectin and ICAM-1)
on ECs [100]. PMV also interact directly with leukocytes.
Consequently, the expression of adhesion receptors such as
CD11b and CD32 and secretion of TNF-a, IL-1b and IL-6 were
up-regulated in THP-1 cells [106]. Furthermore, P-selectin
expressed on PMV acted as an adhesive bridge between HL-60
neutrophilic cells, leading to the formation of homotypic leuko-
cyte aggregates in flow [117].
Thus, it is clear that PMV increase in the circulation during
inflammatory disease. However, at present, it is unknown whether
this is a cause or consequence of pathology. Nevertheless, PMV
appear to have the potential to amplify inflammation by virtue of
the interaction with both leukocytes and ECs.
The role of platelets in leukocyte recruitment in IR injury
Ischemia and reperfusion (IR) injury is a key contributor to the
pathology of cardiovascular and cerebrovascular infarction
(i.e. stroke and heart attack). It may also occur as a complication
of reconstructive vascular surgery or organ transplantation. It is
widely recognised that reperfusion of ischemic tissue exacerbates
tissue damage by inducing a marked inflammatory response
[118]. It is thus pertinent to consider the role of platelets in
leukocyte recruitment, a process which is fundamental to the
progression of IR injury [119–122].
Using electron microscopy and immuno-histochemistry,
Cywes et al. [123, 124] demonstrated the involvement of platelets
in IR injury. They noted platelet accumulation in rat and human
livers subject to cold perfusion as a means of preservation prior to
transplant (otherwise called preservation injury), a process that
imposes an ischaemic insult on the tissue which is reperfused
upon transplant. Since then, platelets have been implicated in the
progression of IR injury during transplant of other organs
including the heart [125], lung [126], liver [124, 127] and
pancreas [128]. Ischemia and reperfusion leads to the activation
and accumulation of platelets within vascular beds early after
reperfusion [129], and platelets are among the first cells recruited
to the site of injury [130]. Intravital microscopy has demonstrated
that platelets interact with numerous vascular beds in the mouse
liver (arterioles, sinusoidal capillaries and venules) after ischemia
followed by as little as 20 minutes of reperfusion. The injury
induced resulted in hepatocellular and microvascular injury and
failure of sinusoidal perfusion [127, 131, 132]. Interestingly, the
extent of platelet recruitment to the vascular endothelium is
dependent upon the duration of ischemia, and not directly to the
duration of reperfusion [127]. P-selectin plays an important role in
the adhesion of platelets to the vessel wall during post-ischeamic
reperfusion [58, 130, 131, 133–136]. However, the source of
P-selectin which mediates these processes is unclear. Different
studies indicate that EC [58, 130, 132, 134] or platelet-derived
P-selectin [133] or both pools of the molecule [133] are involved
in the recruitment of platelets to ECs. Khandoga et al. [131]
described an interaction between fibrinogen deposited on ICAM-
1 of post-ischaemic ECs, which resulted in platelet deposition in
the liver [131], while a number of studies identified platelet
aIIbb3 as the counter ligand for fibrinogen deposited in arterioles
and venules following ischemia of different tissues [133, 137–
139]. Others have shown roles for reactive nitrogen species [140],
angiotensin II type 1-receptors [AT(1)] [141], endothelin-A [142]
and lymphocyte derived IFN-g [143] in promoting the adhesion of
platelets to the post-ischaemic vasculature.
There is also substantial evidence that platelets are responsible
for a proportion of the leukocyte recruitment observed after
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reperfusion of ischemic tissue. Thus, Lefer et al. [144] showed that
platelets were important for neutrophil recruitment during
reperfusion of isolated rat hearts that had been subject to
ischaemia. A number of studies using intravital imaging of the
vasculature after ischaemia and reperfusion showed that platelets
were important for leukocyte recruitment in the microcirculation of
the mesentery [145], the small intestine [146], in cerebral vessels,
as well as in the retina [134]. Not surprisingly, they all reported a
central role for P-selectin in the recruitment of leukocytes.
Platelet-mediated leukocyte adhesion has also been directly
implicated in the process of reperfusion injury. Thus, platelets
contributed to neutrophil-mediated cardiac dysfunction of isolated
perfused rat hearts when mixtures of these cells were perfused
after ischaemia [144]. Importantly, platelet depletion during IR
preserves organ function in a number of models. Thus, the canine
pancreas [128] and liver [147] benefited from such a strategy.
Singbartl et al. [148] showed that platelet P-selectin was necessary
for neutrophil-mediated acute ischemic renal failure in mice. In
addition, in rats, the retinal microcirculation was spared if animals
were rendered thrombocytopenic 4 hours prior to ischemia and
reperfusion [134].
Thus, platelets are efficiently recruited during the reperfusion of
ischemic tissue, and play a role in the recruitment of inflammatory
leukocytes, which in turn are responsible for tissue damage.
Moreover, blockade of platelet adhesion to post-ischemic vessels,
their removal from the circulation prior to ischaemia, or the
inhibition of platelet borne P-selectin, can significantly attenuate
the severity of reperfusion injury. However, other studies have
shown protective effects of platelet-neutrophil aggregate in reso-
lution of inflammatory responses in the microcirculation during IR
[149]. Indeed, it appears that platelet–neutrophil interactions allow
release of the pro-resolving lipid, lipoxin A4 via fpr2/3, which
controls formation of platelet–neutrophil aggregates. Similarly,
production of maresin-1, a pro-resolving mediator, also depends
upon interaction of neutrophils with platelets in a model of acute
lung injury [150]. Indeed, the process of trans-metabolic produc-
tion of pro-resolving mediators by platelet–leukocyte aggregates
in inflammation is a burgeoning field, and the interested reader
is directed to several excellent reviews of this area.
Downstream consequences of platelet–leukocyte
interactions for leukocyte function
The consequences of platelet binding for leukocyte function and
fate have not been extensively investigated. However, acute
modifications to leukocyte surface receptors are documented.
Thus, in heterotypic aggregates, monocyte L-selectin is shed
[151], while the expression and activity of b1- and b2-integrins is
increased [65, 151–154]. Changes in the markers that define
monocyte subsets are also altered by platelet binding. Thus, in a
PGE2 driven process, CD16 on monocytes was increased in
heterotypic aggregates formed in vivo after influenza vaccination
or in vitro by mixing monocytes with platelets [155].
Leukocyte function after adhesion and activation on mono-
layers of activated platelets also changes. Thus, neutrophils
activated on this substrate by IL-8, fMLP or C5a, released more
neutrophil elastase than neutrophils in suspension. This process
required b2-integrin (CD11b/CD18)-mediated binding to the
platelets, and the production of LTB4 [33]. Neutrophils also
receive signals from platelet adhesion receptors (P-selectin and
CD31) which regulate the direction [32] and the velocity [31] of
their migration. Platelet monolayers also supported the migration
of adherent neutrophils into large, homotypic aggregates which
were prone to detachment and dissemination downstream by flow,
in a model of embolus formation [156]. The influence of platelet
adhesion and/or exposure to platelet-derived agents such as
chemokines has been reported to influence the function of a
number of lymphocyte subsets, including helper T-cells, cytotoxic
T-cells, regulatory T-cells, B-cells and NK cells. This area of
lymphocyte biology has recently been reviewed and the reader is
directed to the manuscript by Li et al. [65].
An aspect of leukocyte biology that has received surprisingly
little attention is the role of platelet adhesion in the fate of cells as
they differentiate. Scheuerer et al. [157] demonstrated that the
platelet-derived chemokine, CXCL4, promoted the survival and
differentiation of monocytes into macrophages. Interestingly,
monocytes maturing in the presence of oxidised-low density
lipoprotein (Ox-LDL) into foam cells also showed a CXCL4-
dependent increase in esterification and storage of cholesterol
[158]. Using microarray analysis, Gleissner et al. [159] showed
acquisition of a ‘unique transcriptome’ in human monocyte-
derived macrophages when they were differentiated in the
presence of CXCL4. Interestingly, human macrophages differ-
entiated in the presence of CXCL4 were unable to up-regulate
athero-protective genes such as heam oxygenase-1, due to down
regulation of the haemoglobin scavenger receptor, CD16 [3, 160].
In addition, binding of platelets to monocytes via P-selectin
induced the secretion of TNF-a, IL-1b, IL-6, IL-12, CXCL8 and
CCL4 (MIP-1b) [161]. Seta et al. [162] showed that in the
presence of platelets or platelet-derived supernatants containing
CXCL12 (SDF-1), monocytes could differentiate into monocyte-
derived multipotential cells (MOMCs). These authors had previ-
ously described MOMCs as ‘primitive’ cells with the potential to
differentiate into mesenchymal and endothelial lineages [163].
The interaction between platelets and leukocytes as a
therapeutic target in atherosclerosis
As the preceding discussion has demonstrated, platelets can play a
role in the recruitment of leukocytes during inflammation, and this
pathway probably contributes to pathogenesis in atherosclerotic
disease [69, 164]. Indeed, platelets increase the selective recruit-
ment of monocytes to endothelium in animal and human models of
vascular inflammation [45, 151, 164, 165]. In view of this and the
positive association between platelets–leukocyte interaction and
the progression of atherosclerosis, targeting these pathways
represents a therapeutic avenue of potential importance. Figure 3
shows the pathways that are amenable to therapeutic intervention
using currently licensed agents or drugs under development.
The anti-platelet agents currently used in prevention of athero-
thrombotic disease target platelet activation in thrombotic events
[166–168]. While the anti-thrombotic efficacy of guideline-
approved agents such aspirin and P2Y12 receptor antagonists
(clopidogrel, prasugrel and ticagrelor) is well established, recent
evidence suggests they may have additional anti-inflammatory
effects in addition to being platelet activation inhibitors [166–168].
Thus, Aspirin inhibits platelet activation by irreversibly binding to
the platelet cyclooxygenase (COX)-1 enzyme, abolishing the
formation of thromboxane (Tx)A2 [169]. Aspirin is &150 times
more potent at acetylating ser529 on COX-1 than ser516 on its
inducible homologue COX-2 [169]. Thus, at doses used for
prevention of athero-thrombotic disease, aspirin has a negligible
anti-inflammatory effect [166]. It is perhaps not surprising
therefore that these doses of aspirin do not affect platelet or
leukocyte activation and aggregate formation in whole blood [170].
Production of ADP by activated platelets amplifies platelet
responses to activation, e.g. by stabilising platelet aggregation.
ADP acts through the P2Y12 receptor [171]. Thus, the addition of a
P2Y12 antagonist to aspirin offers better protection against athero-
thrombotic ischemic events, especially in patients suffering from
acute coronary syndromes or having undergone percutaneous
coronary intervention [167]. There are currently three anti-platelet
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agents targeting this receptor: clopidogrel, and the newer gener-
ation prasugrel and ticagrelor [171]. In addition to potent
antithrombotic efficacy, treatment with clopidogrel has been
associated with a number of anti-inflammatory effects. In patients
with atherosclerosis, clopidogrel caused a reduction in
circulating CD40L and CCL-5, improved endothelial nitric oxide
bioavailability, reduced platelet P-selectin expression and impaired
formation platelet–leukocyte aggregates [172–177]. Interestingly,
Antonino et al. showed that inhibition of inflammation markers
correlated with inhibition of platelet activation, thus strengthening
the hypothesis that clopidogrel’s anti-inflammatory effects are
driven by inhibition of platelet activation [178]. Prasugrel is a
P2Y12 receptor antagonist with more uniform and potent platelet
inhibition than clopidogrel [171]. Consistent with this, prasugrel
showed a greater reduction in heterotypic platelet–monocyte
aggregates and levels of circulating CD40L [179–181]. Unlike
clopidogrel and prasugrel, which require bioactivation by the liver,
ticagrelor is a direct-acting reversible P2Y12 receptor antagonist
[171]. In trials, ticagrelor was superior to clopidogrel in anti-
thrombotic effects and in reduction of clinical endpoints of
cardiovascular events and death [182]. Despite this, no differences
in inflammatory markers was seen between clopidogrel- and
ticagrelor-treated patients [183]. These studies imply that P2Y12
receptor antagonists have additional anti-inflammatory properties
which go beyond inhibition of platelet activation.
Despite the anti-inflammatory effects seen with current anti-
platelet agents, their use in secondary prevention of cardiovas-
cular disease does not prevent athero-progression in humans
[184]. This may be because their use is initiated late in disease
development, often after an athero-thrombotic event.
Alternatively, we may require a different approach to target this
aspect of disease with greater precision, of which, inhibiting
platelet-mediated leukocyte recruitment could be an important
therapeutic endpoint. As platelet-facilitated leukocyte recruitment
requires P-selectin interactions with PSGL-1 [185], inhibitors of
this thrombo-inflammatory axis are in development. Among the
earliest, a recombinant antagonist (rPSGL-Ig) was promising in
pre-clinical studies. It significantly reduced the formation of
heterotypic aggregates, attenuated infarct size, protected against
IR injury and accelerated thrombolysis in animal models [186–
190]. However, in clinical trials, the molecule showed no benefit
to coronary vessel patency, infarct size or reperfusion and
Figure 3. Targets for therapeutic intervention
in platelet–leukocyte adhesion and in the
platelet-mediated recruitment of leukocytes:
(A) Therapeutic agents that inhibit the adhe-
sive interactions between platelets and
leukocytes or which inhibit the activation of
platelets by antagonising platelet derived
positive feedback loops which amplify the
platelet response to primary activating sti-
muli. (B) Therapeutic agents that inhibit
platelet adhesion to the vessel wall by either
antagonising adhesive pathways directly or
by inhibiting endothelial cell activation in
response to platelet borne activating stimuli.
AA, Arachidonic acid; ADP, Adenosine
diphosphate; a-G, Alpha granule; COX-1,
Cyclooxygenase-1; DG, Dense granule;
P2Y12, ADP receptor; PGG2, Prostaglandin
G2; PSGL1, P-selectin glycoprotein ligand1;
TP, Thromboxane A2 receptor; TxA2,
Thromboxane A2; TxSy, Thromboxane
synthase.
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functional recovery of the myocardium. Indeed, clinical outcomes
were unaltered at 1 or 6 months [191, 192].Consequently,
development was stopped and ongoing studies terminated.
Notwithstanding, novel P-selectin inhibitors are in development.
A small molecule P-selectin antagonist, PSI-697, was shown to
reduce ex vivo thrombus formation in humans, but failed to inhibit
formation of heterotypic aggregates in vivo [71, 193]. Inclacumab,
a human anti-P-selectin antibody, inhibited the formation of
heterotypic aggregates in healthy volunteers and in patients with
elevated numbers of circulating aggregates [72]. Whether these
molecules will confer clinical benefit remains to be seen.
The CD40–CD40L interaction is an important link between
platelet activation and inflammation [194]. Binding of platelet-
released CD40L to CD40 on ECs, monocytes/macrophages, B
cells and smooth muscle cells induces activatory changes that
result in a pro-inflammatory phenotype [194]. Attempts have been
made to block this interaction in order to halt athero-progression.
In animal models, infusion of anti-CD40L antibodies delayed
lesion formation, reduced leukocyte recruitment to the vessel wall
and inhibited athero-progression [195–198]. A humanized anti-
body against CD40L (toralizumab, IDEC-131) was taken to phase
II clinical trials in diseases with a strong inflammatory component
(namely, multiple sclerosis and Crohn’s disease). Toralizumab’s
development was stopped when a strong signal for unexplained
risk of thrombosis emerged [199]. While the reason for throm-
botic risk remains unexplained, development of compounds
targeting the CD40L signalling pathway continues [194].
Intervention in platelet-mediated recruitment of leukocytes
may also halt athero-progression. Platelet activation through the
binding of the GPIb receptor to VWF contributes to leukocyte
recruitment at high shear [200, 201, see above]. Moreover,
blockade of platelet adhesion to arterial endothelium in athero-
sclerotic mice reduces the development of plaques as well as
leukocyte recruitment to lesions [57 and see above]. Numerous
inhibitors, antibodies, peptides and small molecules have been
developed to target this interaction with promising pre-clinical
results. As the prospects for therapies based on targeting this
interaction have recently been discussed, the reader is directed to
the review by Firbas et al. for further information [202]. Platelet
adhesion at sites of vascular injury is an orchestrated event, in
which the collagen receptor GPVI plays an important role [203].
Inhibition of GPVI protected animals from developing athero-
sclerotic lesions in mouse and rabbit models [204]. Revacept, a
dimeric GPVI-Fc, favourably modified plaque morphology in
atherosclerotic rabbits [205] and reduced cerebral infarct size and
oedema in murine stroke [206]. This agent also inhibited
collagen-induced responses in healthy volunteers, and was safe
in a phase I trial [207]. Whether this molecule will have an impact
on athero-progression in humans again remains unknown.
Conclusions and future perspectives
There is now strong evidence that platelet–leukocyte interactions
within the vasculature increase in cardiovascular disease, or even
upon acquisition of risk factors for such diseases (e.g. hyperten-
sion or dyslipidaemia). A major question to be answered is
whether these interactions are consequential or causal in inflam-
matory disease. Certainly, platelets are important in disease
progression in animal models of atherosclerosis. Moreover, both
in vivo and in vitro data suggests that part of their contribution to
pathology is by recruitment of leukocytes to the vessel wall.
Apparently direct interaction of platelets with arterial ECs can
lead to this increase in leukocyte trafficking. Interestingly, there is
sufficient evidence to suggest that this process selectivity recruits
monocytes, which are the precursors of inflammatory foam cells
in atherosclerotic plaque. Other modes of platelet leukocyte
interaction that lead to leukocyte recruitment should not be
discounted. The formation of heterotypic aggregates in circulating
blood is known to increase in many pathologies, including
cardiovascular diseases. However, whether these interactions are
consequential or causal of disease remains to be determined
experimentally. The developing field of microvesicle biology is
likely to have an important influence on our understanding of
platelet-mediated leukocyte recruitment in cardiovascular dis-
eases. PMV play an important role in the thrombotic disease and
coagulopathies [208] and they have been shown to interact with
ECs in vitro, resulting in the recruitment of leukocytes. Like
platelets, PMV form heterotypic aggregates with leukocytes in
whole blood (unpublished observations). Again, whether these
interactions are consequential or causal of disease remains to be
determined experimentally.
So far, the known routes of platelet-mediated leukocyte
recruitment are based on adhesion receptors and signalling
pathways that regulate haemostasis and leukocyte trafficking
during inflammation. However, it would be naı¨ve to think that
these represent an exhaustive list. Probably, new adhesive and
regulatory pathways are still to be described. Indeed, the
identification of CLEC-2 [209], a novel activation receptor on
platelets is an exemplar of such a scenario. The only known
physiological ligand for CLEC-2 is podoplanin [210], and Herzog
et al. [211] showed that interactions between platelet borne
CLEC-2 and podoplanin on the fibroblastic reticular cells cuffing
high endothelial venules (HEV) of lymph nodes was necessary for
integrity of this vascular bed and to ensure the regulated traffic of
lymphocytes. Although this interaction maintains a homeostatic
pathway in the immune system, it is likely that novel modes of
platelet–leukocyte–vessel wall interaction will support patho-
logical interactions in cardiovascular disease.
Whether intervening in platelet-mediated leukocyte recruit-
ment will have efficacy in cardiovascular disease is still an open
question. In animal models, blockade of platelet activation or
platelet adhesion retards plaque development. However, in
patients with established atherosclerosis, current anti-platelet
therapies do not effect disease progression. Current therapeutic
options were not designed to target platelets involved in these
pathways and this could account for this lack of efficacy. As our
understanding of the biology underlying these pathways increases,
so should our ability to precisely target them with pharmaco-
logical agents.
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